Regeneron Pharmaceuticals, Inc. (REGN) Return on Assets (ROA): 10.82%
Is Regeneron Pharmaceuticals, Inc.’s return on assets (ROA) high or low?
Regeneron Pharmaceuticals, Inc.'s return on assets (ROA) of 10.82% is 36% below its 5-year average of 16.97%, near the low end of its 5-year range (10.82%–31.75%).
As of Thursday, June 18, 2026. 5.09% below its 12-month average of 11.40%.
REGN Return on Assets (ROA) Chart
REGN Average Return on Assets (ROA) Chart
REGN Current vs Average Return on Assets (ROA) Chart
REGN Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
10.82%
RETURN ON ASSETS (ROA) AVG TTM
11.40%
RETURN ON ASSETS (ROA) AVG 3Y
12.40%
RETURN ON ASSETS (ROA) AVG 5Y
16.97%
RETURN ON ASSETS (ROA) AVG 10Y
15.89%
RETURN ON ASSETS (ROA) AVG 15Y
13.87%
RETURN ON ASSETS (ROA) AVG 20Y
6.43%
CURRENT VS TTM AVG
-5.09%
CURRENT VS 3Y AVG
-12.74%
CURRENT VS 5Y AVG
-36.24%
CURRENT VS 10Y AVG
-31.91%
CURRENT VS 15Y AVG
-21.98%
CURRENT VS 20Y AVG
+68.21%
REGN Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. (REGN) | $62.63B | 10.82% | 11.40% | 12.40% | 16.97% |
| Boston Scientific Corporation (BSX)vs › | $66.81B | 8.01% | 5.66% | 4.50% | 3.49% |
| Cencora, Inc. (COR)vs › | $53.91B | 3.12% | 2.14% | 2.52% | 0.85% |
| Cardinal Health, Inc. (CAH)vs › | $53.10B | 2.75% | 2.42% | 0.86% | -0.71% |
| Becton, Dickinson and Company (BDX)vs › | $51.30B | 2.24% | 3.00% | 3.04% | 2.95% |
| Cigna Corporation (CI)vs › | $76.25B | 4.10% | 2.99% | 3.50% | 3.82% |
| Humana Inc. (HUM)vs › | $43.46B | 2.04% | 2.52% | 4.20% | 5.49% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $43.08B | 32.35% | 29.29% | 27.30% | 27.52% |
| Elevance Health Inc. (ELV)vs › | $84.97B | 4.17% | 4.89% | 5.25% | 5.41% |
| HCA Healthcare, Inc. (HCA)vs › | $86.23B | 11.06% | 10.43% | 10.23% | 10.42% |
Asset Efficiency
ROA
10.8%
ROE
14.1%
Regeneron Pharmaceuticals, Inc. Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Regeneron Pharmaceuticals, Inc. Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for Regeneron Pharmaceuticals, Inc. (REGN)?
- The return on assets (ROA) for REGN stock is 10.82%.
- Is Regeneron Pharmaceuticals, Inc.'s return on assets (ROA) high or low?
- Regeneron Pharmaceuticals, Inc.'s return on assets (ROA) of 10.82% is 36% below its 5-year average of 16.97%, near the low end of its 5-year range (10.82%–31.75%).
- What is the TTM average return on assets (ROA) for Regeneron Pharmaceuticals, Inc. (REGN)?
- The TTM average return on assets (ROA) for REGN stock is 11.40%.
- What is the 3Y average return on assets (ROA) for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 3Y average return on assets (ROA) for REGN stock is 12.40%.
- What is the 5Y average return on assets (ROA) for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 5Y average return on assets (ROA) for REGN stock is 16.97%.
- What is the 10Y average return on assets (ROA) for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 10Y average return on assets (ROA) for REGN stock is 15.89%.
- What is the 15Y average return on assets (ROA) for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 15Y average return on assets (ROA) for REGN stock is 13.87%.
- What is the 20Y average return on assets (ROA) for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 20Y average return on assets (ROA) for REGN stock is 6.43%.
Regeneron Pharmaceuticals, Inc. Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 11.11% |
| 2024-12-31 | 11.69% |
| 2023-12-31 | 11.95% |
| 2022-12-31 | 14.85% |
| 2021-12-31 | 31.75% |
| 2020-12-31 | 20.47% |
| 2019-12-31 | 14.29% |
| 2018-12-31 | 20.83% |
| 2017-12-31 | 13.67% |
| 2016-12-31 | 12.84% |
| 2015-12-31 | 11.34% |
| 2014-12-31 | 8.99% |
| 2013-12-31 | 14.38% |
| 2012-12-31 | 36.06% |
| 2011-12-31 | -16.75% |
| 2010-12-31 | -9.59% |
| 2009-12-31 | -9.15% |
| 2008-12-31 | -12.34% |
| 2007-12-31 | -11.28% |
| 2006-12-31 | -17.49% |
| 2005-12-31 | -22.54% |
| 2004-12-31 | 8.81% |
| 2003-12-31 | -22.41% |
| 2002-12-31 | -31.76% |
| 2001-12-31 | -15.38% |
| 2000-12-31 | -11.15% |
| 1999-12-31 | -16.86% |
| 1998-12-31 | -5.48% |
| 1997-12-31 | -6.89% |
| 1996-12-31 | -23.55% |
Related Metrics
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Leonard S. Schleifer